Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Atypical Chemokine Receptor 2 Antibodies

Close filters
No results were found for the filter!
NEW
pS348/pS350-ACKR2 (phospho-Atypical Chemokine Receptor 2 Antibody)
pS348/pS350-ACKR2 (phospho-Atypical Chemokine...
Serine348/Serine350 (S348/S350) is major phosphorylation site of the Atypical Chemokine Receptor 2 (ACKR2). The pS348/pS350-ACKR2 antibody detects phosphorylation in response to agonists. S348/S350 phosphorylation is likely to be...
$ 375.00 *
NEW
Validation of the Atypical Chemokine Receptor 2 in transfected HEK293 cells.
ACKR2 (non-phospho), Atypical Chemokine...
The non-phospho-ACKR2 receptor antibody is directed against the distal part of the carboxyl-terminal tail of human ACKR2. It can be used to detect total ACKR2 receptors in Western blots independent of phosphorylation. The...
$ 300.00 *

ACKR2

The atypical chemokine receptor 2 (ACKR2) acts as chemokine scavenger (also known as chemokine decoy receptor) to downregulate inflammation or shape chemokine gradients. ACKR2 can sequester a broad range of chemokines including CCL2, CCL3, CCL3L1, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL17, CCL22, CCL23, CCL24, SCYA2/MCP-1, SCY3/MIP-1-alpha, SCYA5/RANTES and SCYA7/MCP-3. Efficient ligand uptake by ACKR2 involves phosphorylation of carboxyl-terminal serine348/serine350 (pS348/pS350-ACKR2). This nomenclature refers to the human ACKR2. This phosphorylation motif is highly conserved across species including mouse, rat and human but corresponds to pS344/pS346-ACKR2 in mice. For more information on ACKR2 pharmacology please refer to the IUPHAR database. For further reading refer to:

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467. PubMed PMID: 24218476; PubMed Central PMCID: PMC3880466.

The atypical chemokine receptor 2 (ACKR2) acts as chemokine scavenger (also known as chemokine decoy receptor) to downregulate inflammation or shape chemokine gradients. ACKR2 can sequester a... read more »
Close window
Atypical Chemokine Receptor 2 Antibodies

ACKR2

The atypical chemokine receptor 2 (ACKR2) acts as chemokine scavenger (also known as chemokine decoy receptor) to downregulate inflammation or shape chemokine gradients. ACKR2 can sequester a broad range of chemokines including CCL2, CCL3, CCL3L1, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL17, CCL22, CCL23, CCL24, SCYA2/MCP-1, SCY3/MIP-1-alpha, SCYA5/RANTES and SCYA7/MCP-3. Efficient ligand uptake by ACKR2 involves phosphorylation of carboxyl-terminal serine348/serine350 (pS348/pS350-ACKR2). This nomenclature refers to the human ACKR2. This phosphorylation motif is highly conserved across species including mouse, rat and human but corresponds to pS344/pS346-ACKR2 in mice. For more information on ACKR2 pharmacology please refer to the IUPHAR database. For further reading refer to:

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467. PubMed PMID: 24218476; PubMed Central PMCID: PMC3880466.

Recently viewed